COMPANY CONTACT: CASI Pharmaceuticals, Inc. Rui Zhang 240-864-2643 ir@casipharmaceuticals.com
Unauthorized reproduction is prohibited
BEIJING, April 26, 2023 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.
2022年1月20日,CASI宣布,其合作伙伴BioInvent International AB(以下简称BioInvent)旗下抗FcyRllB抗体BI-1206获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(Orphan Drug Designation, ODD),用于治疗滤泡性淋巴瘤(Follicular Lymphoma,FL)。
CASI focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics.